Development of a novel pneumococcal vaccine with iron oxide nanoparticle for mucosal immunity
| Project/Area Number |
17K10013
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Infectious disease medicine
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
Ishii Keiko 東北大学, 医学系研究科, 准教授 (00291253)
|
|---|
| Project Period (FY) |
2017-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
|
|---|
| Keywords | 新規肺炎球菌ワクチン / ユニバーサルワクチン / 酸化鉄ナノ粒子 / アジュバント / 感染防御効果 / 肺炎球菌 / ナノ粒子ワクチン / 粘膜免疫 / 粘膜免役 |
|---|
| Outline of Final Research Achievements |
We constructed a novel pneumococcal vaccine, PspA-IONP, consisted of pneumococcal surface protein A (PspA) and iron oxide nanoparticle (IONP) with a novel technique. Intratracheal immunization of mice with PspA-IONP induced high levels of systemic PspA-specific IgG antibody than with PspA alone and mucosal PspA-specific IgA antibody that was not detected with PspA alone. When the PspA-IONP-immunized mice were infected with Streptococcus pneumoniae, bacterial proliferation was suppressed, and survival was markedly improved. These results suggest the availability of PspA-IONP as a mucosal immunity-inducing pneumococcal vaccine.
|
| Academic Significance and Societal Importance of the Research Achievements |
現行の肺炎球菌ワクチンは一部の血清型の菌に有効であるが、ワクチンに含まれない血清型の菌が増加する「血清型置換」の解決が課題となっている。本研究では、すべての血清型の菌に存在するpneumococcal surface protein A（PspA）を酸化鉄ナノ粒子（iron oxide nanoparticle: IONP）に独自の方法で結合させたPspA-IONP を作成し、マウスでその効果を実証した。IONPは吸入用ドライパウダー製剤化を目指したアジュバントであり、他のワクチンにも応用可能である。
|
Report
(4 results)
Research Products
(4 results)
